Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug targets Hard-to-Treat cancers in new trial

NCT ID NCT04659603

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tusamitamab ravtansine (an antibody-drug conjugate) and gemcitabine (a chemotherapy drug)

What this could lead to

If successful, this could point toward a new treatment option for people with certain advanced breast or pancreatic cancers that express the CEACAM5 marker.

What could go wrong

This early-phase trial was terminated, so results are limited. The drug may cause serious side effects like low blood cell counts or eye problems, and it is unclear if it will work better than existing therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma malignant pancreatic neoplasm metastatic carcinoma pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTATIC PANCREATIC CARCINOMA METASTATIC

Contacts and locations

Locations

  • AdventHealth Orlando Site Number : 8400001

    Orlando, Florida, 32804, United States

  • Investigational Site Number : 0320001

    Pergamino, Buenos Aires, B2700CPM, Argentina

  • Investigational Site Number : 0320002

    Rosario, Santa Fe Province, 2000, Argentina

  • Investigational Site Number : 0320003

    Capital Federal, Buenos Aires, 1012, Argentina

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 8420383, Chile

  • Investigational Site Number : 1520002

    Temuco, La Araucanía, 4800827, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, 7500921, Chile

  • Investigational Site Number : 1580001

    Taichung, 40447, Taiwan

  • Investigational Site Number : 1580002

    Tainan, 704, Taiwan

  • Investigational Site Number : 1580003

    Taipei, 11217, Taiwan

  • Investigational Site Number : 3480003

    Budapest, 1122, Hungary

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, 06351, South Korea

  • Investigational Site Number : 4100003

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • Investigational Site Number : 5280001

    Rotterdam, 3015 GD, Netherlands

  • Investigational Site Number : 5280002

    Amsterdam, 1066 CX, Netherlands

  • Investigational Site Number : 5280003

    Utrecht, 3584 CX, Netherlands

  • Investigational Site Number : 6430001

    Moscow, 115478, Russia

  • Investigational Site Number : 6430002

    Saint Petersburg, 197758, Russia

  • Investigational Site Number : 6430004

    Pushkin, Saint- Petersburg, 196603, Russia

  • Investigational Site Number : 7240001

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7240002

    Majadahonda, Madrid, 28222, Spain

  • Investigational Site Number : 7240003

    Madrid, Madrid, Comunidad de, 28046, Spain

  • Investigational Site Number : 7920001

    Istanbul, 34722, Turkey (Türkiye)

  • Investigational Site Number : 7920002

    Izmir, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Adana, 01250, Turkey (Türkiye)

  • Investigational Site Number : 7920004

    Ankara, 06100, Turkey (Türkiye)

  • Massachusetts General Hospital Site Number : 8400002

    Boston, Massachusetts, 02114, United States

  • University of Wisconsin Site Number : 8400004

    Madison, Wisconsin, 53792, United States